All that I really know about 3-71 is that it is potent in vanishingly small amounts, and that it also agonizes the Sigma-1 Receptor. I can't conclude it is the equivalent or better of 2-73. And as for 1066, I know even less.
It's asking a lot of a tiny biotech to have more than one apparent wonder drug.
Well, of course, detection of toxicity will be closely examined in the new human trials of Anavex 3-71.
But, in fact, the molecule has demonstrated no toxicities in any trial, murine or human. Blarcamesine is administered in milligrams (typically 20 to 50). Anavex 3-73 in micrograms, doses a thousandth the size of those of blarcamesine.
As you mentioned, "it takes a very small amount of 3-71 to agonize SR-1.... " This is known and has been demonstrated in murines; but without adverse events.
For either reason (minute dosages, or no experimental evidence of such), the drug is most likely to be utterly safe. Human trials data will definitively decide the matter. Let's see how those turn out.
Understand, my contention of abject safety for Anavex 3-71 was not a suggestion that safety should not or would not be tested. Merely, that it most likely will prove to be safe.